JPRN-UMIN000010963已完成1 期
Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer. - Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer.
Kitasato University School of Medicine Department of Respiratory Medicine0 个研究点目标入组 16 人开始时间: 2013年6月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Severe infection. 2) Severe complications. 3) Uncontrollable pleural or pericardial effusion or ascites. 4) Superior vena cava syndrome. 5) Simultaneous or metachronous double cancers. 6) Symptomatic brain metastases. 7) Prior radiotherapy for primary tumor. 8) Radiotherapy other than primary tumor within 2 weeks. 9) A history of serious drug allergy or severe allergic reaction with albumin. 10) Psycologic illness
研究者
相似试验
招募中
1 期
Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study)gastric cancer with peritoneal metastasisJPRN-UMIN000030909Wakayama Medical University, School of Medicine35
已完成
1 期
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000004729School of Medicine, Keio University40
已完成
1 期
Phase I-II study of combination chemotherapy with Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancerClear cell or mucinous ovarian cancerJPRN-UMIN000005952Osaka university, faculty of medicine40
已完成
1 期
A phase I study of the combination chemotherapy of IRISOX (irinotecan/S-1/oxaliplatin) in gemcitabine-refractory pancreatic cancergemcitabine-refractory pancreatic cancerJPRN-UMIN000022964Kitasato University School of Medicine12
已完成
2 期
A Phase II study of combination chemotherapy with TS-1 and Trastuzumab for patients with HER2 positive advanced or recurrent gastric cancer.advanced or recurrent gastric cancerJPRN-UMIN000008220Osaka medical center for cancer and cardiovascular diseases20